TY - JOUR
T1 - His-Purkinje Conduction System Pacing Following Transcatheter Aortic Valve Replacement
T2 - Feasibility and Safety
AU - Vijayaraman, Pugazhendhi
AU - Cano, Óscar
AU - Koruth, Jacob S.
AU - Subzposh, Faiz A.
AU - Nanda, Sudip
AU - Pugliese, Jessica
AU - Ravi, Venkatesh
AU - Naperkowski, Angela
AU - Sharma, Parikshit S.
N1 - Funding Information:
Dr. Vijayaraman has received honoraria, been a consultant, conducted research, and received fellowship support from Medtronic; has been a consultant for Boston Scientific, Abbott, and Biotronik; and has a patent pending for the His bundle pacing delivery tool. Dr. Cano has been a consultant for Medtronic. Dr. Koruth has been a consultant for Abbott, Farapulse, VytronUS, and CardioFocus; has served on the advisory board for Medtronic and Farapulse; and has received research grants from Farapulse, VytronUS, CardioFocus, Biosense, and Affera, Inc. Dr. Subzposh has received honoraria from Medtronic. Dr. Sharma has received honoraria from Medtronic; and has been a consultant for Medtronic, Abbott, Boston Scientific, and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
Dr. Vijayaraman has received honoraria, been a consultant, conducted research, and received fellowship support from Medtronic; has been a consultant for Boston Scientific, Abbott, and Biotronik; and has a patent pending for the His bundle pacing delivery tool. Dr. Cano has been a consultant for Medtronic. Dr. Koruth has been a consultant for Abbott, Farapulse, VytronUS, and CardioFocus; has served on the advisory board for Medtronic and Farapulse; and has received research grants from Farapulse, VytronUS, CardioFocus, Biosense, and Affera, Inc. Dr. Subzposh has received honoraria from Medtronic. Dr. Sharma has received honoraria from Medtronic and has been a consultant for Medtronic, Abbott, Boston Scientific, and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/6
Y1 - 2020/6
N2 - Objectives: This study aimed to assess the feasibility and success rates of permanent His-Purkinje conduction system pacing (HPCSP) in patients requiring pacing after transcatheter aortic valve replacement (TAVR). Background: TAVR is associated with increased risk for atrioventricular block. HPCSP has the potential to reduce electromechanical dyssynchrony associated with right ventricular pacing. The feasibility and safety of HPCSP in this population are unknown. Methods: Consecutive patients requiring pacemakers after TAVR in whom His bundle pacing (HBP) and/or left bundle branch area pacing (LBBAP) was attempted at 5 centers were included in the study. Implant success rates, pacing characteristics, QRS duration, and left ventricular ejection fraction were assessed. Any procedure-related complications, lead revisions, heart failure hospitalizations, and deaths were documented. Results: HPCSP was successful in 55 of 65 (85%) patients studied. HBP was successful in 29 of 46 patients (63%), and LBBAP was successful in 26 of 28 (93%) patients in whom it was attempted. HBP was more successful in patients with Sapien valves than in those with CoreValves (69% vs. 44%; p < 0.05). LBBAP was associated with lower pacing thresholds and higher R-wave amplitudes at implantation compared with HBP (0.64 ± 0.3 at 0.5 ms vs. 1.4 ± 0.8 at 1 ms; p < 0.001; 14 ± 8 mV vs. 5.5 ± 5.6 mV; p < 0.001). Pacing thresholds remained stable and left ventricular ejection fraction remained unchanged during a mean follow-up of 12 ± 13.7 months. Conclusions: HPCSP is feasible in the majority of patients requiring pacemakers post-TAVR. Success rates of HBP were lower in patients with CoreValves compared to Sapien valves. LBBAP was associated with higher success rates and lower pacing thresholds compared with HBP.
AB - Objectives: This study aimed to assess the feasibility and success rates of permanent His-Purkinje conduction system pacing (HPCSP) in patients requiring pacing after transcatheter aortic valve replacement (TAVR). Background: TAVR is associated with increased risk for atrioventricular block. HPCSP has the potential to reduce electromechanical dyssynchrony associated with right ventricular pacing. The feasibility and safety of HPCSP in this population are unknown. Methods: Consecutive patients requiring pacemakers after TAVR in whom His bundle pacing (HBP) and/or left bundle branch area pacing (LBBAP) was attempted at 5 centers were included in the study. Implant success rates, pacing characteristics, QRS duration, and left ventricular ejection fraction were assessed. Any procedure-related complications, lead revisions, heart failure hospitalizations, and deaths were documented. Results: HPCSP was successful in 55 of 65 (85%) patients studied. HBP was successful in 29 of 46 patients (63%), and LBBAP was successful in 26 of 28 (93%) patients in whom it was attempted. HBP was more successful in patients with Sapien valves than in those with CoreValves (69% vs. 44%; p < 0.05). LBBAP was associated with lower pacing thresholds and higher R-wave amplitudes at implantation compared with HBP (0.64 ± 0.3 at 0.5 ms vs. 1.4 ± 0.8 at 1 ms; p < 0.001; 14 ± 8 mV vs. 5.5 ± 5.6 mV; p < 0.001). Pacing thresholds remained stable and left ventricular ejection fraction remained unchanged during a mean follow-up of 12 ± 13.7 months. Conclusions: HPCSP is feasible in the majority of patients requiring pacemakers post-TAVR. Success rates of HBP were lower in patients with CoreValves compared to Sapien valves. LBBAP was associated with higher success rates and lower pacing thresholds compared with HBP.
KW - AV block
KW - His bundle pacing
KW - TAVR
KW - conduction system pacing
KW - left bundle branch area pacing
UR - http://www.scopus.com/inward/record.url?scp=85085053280&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2020.02.010
DO - 10.1016/j.jacep.2020.02.010
M3 - Article
C2 - 32553214
AN - SCOPUS:85085053280
SN - 2405-5018
VL - 6
SP - 649
EP - 657
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 6
ER -